CRON - Merus upgraded on ASCO update Citi favors Harpoon after selloff; and more in today's analyst action

Photo by goir/iStock via Getty Images Merus jumps on Citi upgrade Merus (MRUS) shares have climbed ~5.4% in early trading after Citi analyst Yigal Nochomovitz upgraded the stock to buy from neutral. The price target of $31.00 per share implies a premium of ~49.9%. Citing dataset presented by the company at 2021 ASCO Annual Meeting, the analyst expects Zenocutuzumab, the company’s NRG1-targeting candidate against solid tumors, to demonstrate a safety and efficacy profile to support multiple paths for registration. Previously RBC Capital Markets observed insufficient data to have a broader interpretation of Zeno’s clinical benefit despite an ASCO abstract published by the company in May. Cantor remains bullish on Harpoon after the selloff Harpoon Therapeutics (HARP) dropped sharply last Friday after presenting less than favorable data for HPN424 from a Phase 1/2 study in prostate cancer. However, Cantor Fitzgerald analyst Emma Nealon maintains the overweight rating and the price target of $40.00 per share implies

For further details see:

Merus upgraded on ASCO update, Citi favors Harpoon after selloff; and more in today’s analyst action